Logo image of KHRN.CA

KHIRON LIFE SCIENCES CORP (KHRN.CA) Stock Fundamental Analysis

TSX-V:KHRN - TSX Venture Exchange - CA49374L3065 - Common Stock - Currency: CAD

0.04  0 (0%)

Fundamental Rating

2

Taking everything into account, KHRN scores 2 out of 10 in our fundamental rating. KHRN was compared to 33 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of KHRN have multiple concerns. KHRN shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KHRN had negative earnings in the past year.
KHRN had a negative operating cash flow in the past year.
KHRN.CA Yearly Net Income VS EBIT VS OCF VS FCFKHRN.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M

1.2 Ratios

The profitability ratios for KHRN are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KHRN.CA Yearly ROA, ROE, ROICKHRN.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

1.3 Margins

With a Gross Margin value of 19.51%, KHRN perfoms like the industry average, outperforming 47.73% of the companies in the same industry.
In the last couple of years the Gross Margin of KHRN has declined.
The Profit Margin and Operating Margin are not available for KHRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.81%
GM growth 5YN/A
KHRN.CA Yearly Profit, Operating, Gross MarginsKHRN.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -500 -1K -1.5K -2K

More info and screens

2

2. Health

2.1 Basic Checks

KHRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KHRN has been increased compared to 1 year ago.
The debt/assets ratio for KHRN is higher compared to a year ago.
KHRN.CA Yearly Shares OutstandingKHRN.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M
KHRN.CA Yearly Total Debt VS Total AssetsKHRN.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -5.28, we must say that KHRN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of KHRN (-5.28) is worse than 70.45% of its industry peers.
KHRN has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
KHRN's Debt to Equity ratio of 0.05 is fine compared to the rest of the industry. KHRN outperforms 68.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -5.28
ROIC/WACCN/A
WACC6.71%
KHRN.CA Yearly LT Debt VS Equity VS FCFKHRN.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M

2.3 Liquidity

KHRN has a Current Ratio of 1.91. This is a normal value and indicates that KHRN is financially healthy and should not expect problems in meeting its short term obligations.
KHRN's Current ratio of 1.91 is in line compared to the rest of the industry. KHRN outperforms 59.09% of its industry peers.
KHRN has a Quick Ratio of 1.91. This is a bad value and indicates that KHRN is not financially healthy enough and could expect problems in meeting its short term obligations.
KHRN's Quick ratio of 0.91 is in line compared to the rest of the industry. KHRN outperforms 43.18% of its industry peers.
Industry RankSector Rank
Current Ratio 1.91
Quick Ratio 0.91
KHRN.CA Yearly Current Assets VS Current LiabilitesKHRN.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

7

3. Growth

3.1 Past

The earnings per share for KHRN have decreased strongly by -59.04% in the last year.
KHRN shows a strong growth in Revenue. In the last year, the Revenue has grown by 38.20%.
Measured over the past years, KHRN shows a very strong growth in Revenue. The Revenue has been growing by 143.00% on average per year.
EPS 1Y (TTM)-59.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.56%
Revenue 1Y (TTM)38.2%
Revenue growth 3Y143%
Revenue growth 5YN/A
Sales Q2Q%-3.82%

3.2 Future

The Earnings Per Share is expected to grow by 25.99% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 40.15% on average over the next years. This is a very strong growth
EPS Next Y39.13%
EPS Next 2Y31.88%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year36.43%
Revenue Next 2Y38.09%
Revenue Next 3Y45.7%
Revenue Next 5Y40.15%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
KHRN.CA Yearly Revenue VS EstimatesKHRN.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
KHRN.CA Yearly EPS VS EstimatesKHRN.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 -0.1 -0.2 -0.3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

KHRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KHRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KHRN.CA Price Earnings VS Forward Price EarningsKHRN.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KHRN.CA Per share dataKHRN.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1

4.3 Compensation for Growth

KHRN's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.88%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

KHRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KHIRON LIFE SCIENCES CORP

TSX-V:KHRN (5/5/2023, 7:00:00 PM)

0.04

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.47%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.19M
Analysts45.71
Price Target0.1 (150%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)0.99%
Max EPS beat(2)0.99%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.31%
Min Revenue beat(2)-30.18%
Max Revenue beat(2)-16.44%
Revenue beat(4)1
Avg Revenue beat(4)-33.87%
Min Revenue beat(4)-93.32%
Max Revenue beat(4)4.48%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.45
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 0.36
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.09
BVpS0.15
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.51%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.81%
GM growth 5YN/A
F-Score2
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 143.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.91
Quick Ratio 0.91
Altman-Z -5.28
F-Score2
WACC6.71%
ROIC/WACCN/A
Cap/Depr(3y)345.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.56%
EPS Next Y39.13%
EPS Next 2Y31.88%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)38.2%
Revenue growth 3Y143%
Revenue growth 5YN/A
Sales Q2Q%-3.82%
Revenue Next Year36.43%
Revenue Next 2Y38.09%
Revenue Next 3Y45.7%
Revenue Next 5Y40.15%
EBIT growth 1Y14.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.73%
EBIT Next 3Y30.54%
EBIT Next 5YN/A
FCF growth 1Y43.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.83%
OCF growth 3YN/A
OCF growth 5YN/A